FDA approves Arvinas and Pfizer's Veppanu, a PROTAC protein degrader, in ESR1-mutated breast cancer
Vepdegestrant more than doubled median progression-free survival against fulvestrant in ESR1-mutated advanced breast cancer, at 5.0 months against 2.1.